markets

Windward Bio Debuts on Nasdaq, Shares Surge 68% on IPO Day

Summarized from All Financial Services & Investing

Clinical-stage biotech Windward Bio priced its IPO at $17 per share and closed its first trading day at $28.50 on Nasdaq.

Windward Bio Debuts on Nasdaq, Shares Surge 68% on IPO Day

Windward Bio, a clinical-stage biotechnology company backed by Qiming Venture Partners, made its public market debut on Nasdaq on November 13, 2026, under the ticker symbol WWB, the Shanghai-based firm announced.

The company priced its initial public offering at $17.00 per share. By the close of its first trading session, shares had risen to $28.50, representing a gain of roughly 68 percent from the offering price — a notably strong first-day performance by recent biotech IPO standards.

Read more Inverse Anthropic ETFs Offer Bears a Way to Bet Against ANT →

Windward Bio operates in the immunology space and is classified as clinical-stage, meaning its pipeline candidates are actively being tested in human trials but have not yet reached commercialization. The company's connection to Qiming Venture Partners, a prominent venture capital firm with deep roots in Chinese life sciences investment, underscores the cross-border nature of the listing.

The Nasdaq debut marks a significant milestone for Windward Bio as it seeks access to U.S. capital markets to advance its immunology research programs. A strong opening-day performance can provide a company with added visibility among institutional investors, though biotech valuations remain closely tied to clinical data readouts in subsequent quarters.

Continue reading at All Financial Services & Investing.

Frequently Asked Questions

Q.What is Windward Bio's Nasdaq ticker symbol?

Windward Bio trades on Nasdaq under the ticker symbol WWB.

Q.What was the IPO price for Windward Bio shares?

Windward Bio priced its IPO at $17.00 per share and closed its first trading day at $28.50.

Q.Who is the venture capital backer of Windward Bio?

Windward Bio is a portfolio company of Qiming Venture Partners, a venture capital firm active in life sciences investment.

More in markets →